Table 1.
Baseline Characteristics
| Characteristic | Sorafenib-based (n=35) |
HAIC-based (n=38) |
p-value |
|---|---|---|---|
| Age, yr | 58.3±9.5 | 53.0±11.6 | 0.037 |
| Male sex | 30 (86) | 30 (79) | 0.450 |
| Etiology | |||
| CHB/CHC/alcohol/cryptogenic, n | 24/2/6/3 | 33/2/2/1 | 0.230 |
| CHB or CHC+alcohol | 12 (46) | 14 (54) | 0.820 |
| Child-Pugh class A/B | 24 (69)/11 (31) | 27 (71)/11 (29) | 0.817 |
| Performance status by ECOG 0-1/2/3 | 24 (69)/9 (25)/2 (6) | 29 (77)/7 (18)/2 (5) | 0.892 |
| Prior treatment | |||
| None/curative (resection, RFA) | 21 (60)/14 (40) | 29 (76)/9 (24) | 0.134 |
| Tumor type nodular/infiltrative | 16 (46)/19 (54) | 14 (37)/24 (63) | 0.441 |
| LN metastasis | 14 (40) | 13 (34) | 0.609 |
| Solid organ metastasis | 16 (46) | 2 (5.3) | <0.001 |
| Lung/adrenal/bone/peritoneum, n | 12/2/1/1 | 0/1/0/1 | |
| Laboratory findings | |||
| Platelet count, ×103/µL | 196±105 | 162±83 | 0.133 |
| Albumin, g/dL | 3.53±0.40 | 3.48±0.43 | 0.623 |
| AST, IU/mL | 103±98 | 89±63 | 0.484 |
| ALT, IU/mL | 56±47 | 58±35 | 0.835 |
| Total bilirubin, mg/dL | 1.16±0.55 | 1.04±0.48 | 0.302 |
| PT, INR | 1.16±0.12 | 1.13±0.13 | 0.270 |
| AFP, ng/mL | 69,745±21,274 | 71,341±14,823 | 0.971 |
| PIVKA-II, mAU/mL | 1,437±824 | 1,361±821 | 0.714 |
Data are presented as mean±SD or number (%).
HAIC, hepatic arterial infusion chemotherapy; CHB, chronic hepatitis B; CHC, chronic hepatitis C; ECOG, Eastern Cooperative Oncology Group; RFA, radiofrequency ablation; LN, lymph node; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II.